Top Tweets for #AASLD2026
🇨🇳CTTQ and $GSK ’s ASO candidate Bepirovirsen Phase 3 B-Well data at #AASLD2026 : High durability of functional cure in chronic HBV
Bepirovirsen (approved in Japan and US; under priority review in China) presented final analyses and long-term follow-up.
B-Well 1 & 2 (n=1838, NA-suppressed, HBsAg 100–3000 IU/mL):
- Functional cure (FC) at Week 72: 20% and 19% with bepirovirsen vs 0% placebo
- Among patients who achieved FC at Week 72 and completed Week 96 follow-up: 90–92% maintained FC off all therapy
B-Sure long-term follow-up:
- Some responders maintained FC for at least 15 months (off all HBV treatment for >21 months)
- 95% of enrolled FC responders still maintained FC at entry into B-Sure
Additional presentations covered early predictors of response (e.g., Week 12 HBsAg) and mechanistic insights.
🇨🇳Huadong Medicine’s DR10624 (FGF21R/GCGR/GLP-1R triple agonist) shows strong Phase 2 data in MASLD/MASH at #AASLD2026
Late-breaking oral presentation of the China Phase 2 DR10624-202 study (weekly SC for 12 weeks).
Key efficacy (Week 12):
- 50 mg: 80.3% relative reduction in liver fat content (LFC) vs baseline
- 94.1% of patients achieved ≥50% LFC reduction; 87.7% achieved ≥70%
- 81.8% of patients in 50 mg group normalized liver fat (LFC <5%; baseline mean 19.7%)
- Significant LFC reduction already seen by Week 6
- 70.4% of patients in 25 mg group achieved ≥30% reduction in liver stiffness (LSM)
- Improvements in FIB-4, APRI, FAST, ALT, AST, ALP, GGT
- Favorable changes in lipids (TG, TC, non-HDL-C, LDL-C, VLDL-C, ApoB), adiponectin ↑, uric acid and body weight ↓
An incredible #AASLD2026 in Denver! 🏔️
An exciting year of research with our team at the Cleveland Clinic, featuring 2 abstract parallel oral sessions, a plenary presentation as second author, and a Poster of Distinction!
Our research explored meaningful questions in hepatology, including liver transplant outcomes in HCC, waitlist disparities, and the influence of liver disease etiology on patient outcomes.
A special highlight was collaborating with @drislambadr on meaningful research, including our Poster of Distinction. Grateful to him for presenting our collaborative work and to all our mentors and coauthors who made these projects possible!
Beyond presenting our findings, it was inspiring to learn about emerging therapies, groundbreaking research, and the future of liver disease care.
Leaving Denver with new perspectives, valuable connections, and renewed motivation to continue advancing hepatology research!
#TheLiverMeeting #Hepatology #LiverTwitter #TLM26 @AASLDtweets
Congratulations to CASL member Dr. @MacparlandSonya (@UHN_Research) on the Hans Popper State of the Art Lecture at #AASLD2026, and thank you to everyone who joined our CASL Reception Night.
See you at CLM 2027 in Calgary, May 13-16: https://t.co/bO2D6M9SYh
#CLM2027
Wrapping up a productive and enjoyable time at the #AASLDLiverMeeting2026…had a wonderful time interacting with colleagues, presenting and discussing research, with some time to see the local sights. 📊🌆
#LiverMeeting2026
#MedTwitter
#Hepatology
#AASLD2026
Alnylam collaborator Regeneron presented promising first-in-human results for an investigational RNAi therapeutic (also known as an siRNA therapeutic) in patients with metabolic dysfunction-associated steatotic liver disease (#MASLD) during an oral session at #AASLD2026 that were also published by NEJM. https://t.co/11mdnBhtLd
#siRNA #RNAi #RNAiTherapeutics
One of the greatest privileges of being at #AASLD2026 is the opportunity to learn from and connect with mentors who continue to inspire and guide. @ArunJSanyalVCU @saulkarpen @DrLoomba
Especially grateful to @juanpabloarab for his mentorship, encouragement, and for giving the opportunity that made this journey possible. Your support has meant so much.
Always learning, always grateful, and inspired to keep growing.
#Hepatology #Mentorship #AASLD2026 #TLM2026 @UConnIM @VCU_Liver
A new study, presented today at #AASLD2026, found that treatment with efinopegdutide resulted in a significantly greater proportion of participants with MASH resolution without worsening of fibrosis compared with placebo. https://t.co/BzyfSsYzAG @AASLDtweets #TLM2026
Reuniting with my mentor @ReibergerThomas in AASLD, shortly after I finished my research fellowship in Vienna! #AASLD2026
Can metabolic therapies prevent liver cancer?
Emerging evidence is promising, but definitive RCT data for HCC prevention are still lacking.
Wait for an RCT? Or act now?
Thought provoking discussions at #AASLD2026 #JSH
@AASLDtweets @ELC_APAGE
#LiverCancer #MASLD
Honoured to receive the 2026 International Early Career Investigator Award from the AASLD Foundation for our research on Metabolic Hepatitis B (Met-B) and hepatocellular carcinoma risk.
Grateful to my mentors and team at ILBS, New Delhi.
#AASLD2026 #Hepatology #HCC
We presented positive results for our investigational siRNA therapeutic in metabolic dysfunction-associated steatotic liver disease (#MASLD) at #AASLD2026 that were also published by @NEJM.
Learn more: https://t.co/LpJBeZp6ti
#AASLD2026 Fatty liver disease
Excited for another insightful session at #AASLD2026 in Denver! 🏔️
Happening now !
Dr. Monica Tincopa’s @MonicaTincopa discussion on managing patients with #MASLD and advanced liver fibrosis, focusing on practical, evidence-based strategies to optimize liver and metabolic health.
#TheLiverMeeting #Hepatology #LiverDisease #TLM2026
🧠🤖 Exciting insights from the AI in Clinical Hepatology training session at #AASLD2026 in Denver!
Exploring how AI can transform clinical decision-making, evidence-based practice, and hepatology education.
💡 Key takeaway: AI is a powerful tool, but critical appraisal and clinical judgment remain essential!
#TheLiverMeeting #Hepatology #ArtificialIntelligence #MedEd
Last Seen Hashtags on Sotwe
minichatttt
Seen from Spain
teenageers
Seen from India
anxiouspandaaaa
Seen from United States
rawbreeder
前列腺高潮
Seen from United States
forced daughter ()*+filter:native_video
Seen from Pakistan
manisatraveſti
Seen from Turkey
sister #edit
Seen from Japan
brosis
Seen from Guatemala
slut
Seen from Chile
Most Popular Users
Elon Musk 
@elonmusk
241M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.6M followers